Pu, Yeong-Shiau <br/><br/>
Arsenic trioxide as a novel anticancer agent against human transitional carcinoma--characterizing its apoptotic pathway.  [electronic resource] 

 -  Anti-cancer drugs  Mar 2002 
 - 293-300 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0959-4973 
<br/><br/><label>Standard No.: </label>10.1097/00001813-200203000-00011  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--therapeutic use<br/>Apoptosis--drug effects<br/>Arsenic Trioxide<br/>Arsenicals--therapeutic use<br/>Buthionine Sulfoximine--therapeutic use<br/>Carcinoma, Transitional Cell--drug therapy<br/>Caspase 3<br/>Caspases--metabolism<br/>Cisplatin--pharmacology<br/>DNA, Neoplasm--drug effects<br/>Drug Resistance, Neoplasm<br/>Enzyme Activation<br/>G1 Phase--drug effects<br/>Humans<br/>Membrane Potentials--drug effects<br/>Mitochondria--metabolism<br/>Oxides--therapeutic use<br/>Reactive Oxygen Species--metabolism<br/>Signal Transduction<br/>Tumor Cells, Cultured--drug effects<br/>Urinary Bladder Neoplasms--drug therapy